Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150447 | 1.00 | ALDH1A1 (0.68) | ALDH1A1NPC1TAAR1HTR3ATSHR | |
| SCHEMBL4942727 | 1.00 | ALDH1A1 (0.68) | ALDH1A1NPC1TAAR1HTR3ATSHR | |
| Hydrochloric Acid SCHEMBL26098210 | 0.98 | ALDH1A1 (0.66) | ALDH1A1NPC1TAAR1HTR3ATSHR | |
| SCHEMBL6695879 | 0.85 | ALDH1A1 (0.64) | ALDH1A1NPC1KDM4ELOXL2MEN1 | |
| SCHEMBL1983480 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1TSHRKDM4EMEN1 | |
| SCHEMBL18913904 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1TSHRKDM4EMEN1 | |
| SCHEMBL2368297 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1TSHRKDM4EMEN1 | |
| SCHEMBL240466 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1TSHRKDM4EMEN1 | |
| SCHEMBL28436171 | 0.82 | ALDH1A1 (0.70) | ALDH1A1NPC1TSHRKDM4EMEN1 | |
| SCHEMBL1023275 | 0.82 | ALDH1A1 (0.70) | ALDH1A1NPC1TSHRKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114874143-A | Regulator containing pyrazole derivatives, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2962687-B1 | TAU AGGREGATION INHIBITOR | THE DOSHISHA (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-9907799-B2 | Tau aggregation inhibitor | THE DOSHISHA (JP) | 2018-03-06 | — | — | US | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160030437-A1 | TAU AGGREGATION INHIBITOR | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2962687-A1 | TAU AGGREGATION INHIBITOR | The Doshisha (JP) | 2016-01-06 | — | — | EP | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| US-20030158237-A1 | Combination of antioxidant substances for the treatment of alzheimer's disease | COLBA R & D INC. (CA) | 2003-08-21 | — | — | US | disclosed |
| CN-1419541-A | Pharmaceutically active pyrrolidine derivatives as BAX inhibitors | APPLIED RES SYSTEMS AKS HOLDIN (NL) | 2003-05-21 | — | — | CN | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0459730-A2 | Anti-tumour compounds | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-3947456-A | ANTIDEPRESSANTS | HOFFMAN-LA ROCHE INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | ALDH1A1 3384/4885NPC1 4009/4885TAAR1 271/4885 |
| US-20160030437-A1 | TAU AGGREGATION INHIBITOR | MAPT, PSEN2, PSEN1 | ALDH1A1 4120/4885NPC1 1177/4885TAAR1 3190/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | ALDH1A1 2019/4885NPC1 463/4885TAAR1 1851/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | ALDH1A1 3249/4885NPC1 1842/4885TAAR1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.